Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

GLIOMATCH

Financiado

The malignant Glioma immuno-oncology matchmaker: towards data-driven precision m...

The malignant Glioma immuno-oncology matchmaker: towards data-driven precision medicine using spatially resolved radio-multiomics "Adult and paediatric malignant glioma (GBM and pHGG) remain among the most difficult-to-treat cancers with 5-year survival rates of <5% despite intensive standard-of-care therapy. The differences among patients and the heterogene... ver más

31/12/2028

KU Leuven

11M€

Presupuesto del proyecto: 11M€

Líder del proyecto

KATHOLIEKE UNIVERSITEIT LEUVEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 17 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-12-07

HORIZON-MISS-2023-CANCER-01-01: Addressing poorly-understood tumour... ExpectedOutcome:Proposals under this topic should aim to deliver results that are directed and tailo...

I+D

Cerrada hace 1 año

0% 100%

17 Participantes

KU Leuven

4.27M€ | Lider

UDUS

1.13M€ | Participante

BELSPO

292.50K€ | Participante

FUNDACIO PRIVADA PER LA RECE...

197.50K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

IOO - Improving IO IOO: a novel assay to predict patient response to immune che... 4M€ Cerrado

RTI2018-098682-B-I00 APRENDIZAJE PROFUNDO ESPACIO-TEMPORAL PARA LA PREDICION DE R... 140K€ Cerrado

HD-BRECA Integrating longitudinal multi-modal profiling of metastatic... 165K€ Cerrado

CNS2023-143848 Cáncer 200K€ Cerrado

ProstOmics Tissue is the issue a multi omics approach to improve pro... 2M€ Cerrado

EQC2018-004733-P ADQUISIÓN DE EQUIPO PARA IDENTIFICACIÓN Y RECUPERACIÓN DE CÉ... 171K€ Cerrado

Duración del proyecto: 60 meses Fecha Inicio: 2023-12-07
Fecha Fin: 2028-12-31

Líder del proyecto

KATHOLIEKE UNIVERSITEIT LEUVEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 11M€

Descripción del proyecto "Adult and paediatric malignant glioma (GBM and pHGG) remain among the most difficult-to-treat cancers with 5-year survival rates of <5% despite intensive standard-of-care therapy. The differences among patients and the heterogeneous and plastic nature of each individual tumour have resulted in all therapeutic clinical trials failing during the past 20 years. Recently, immunotherapy has been showing great promise, but only in subsets of patients. Identifying those patients cannot be done a priori as biomarkers are still largely missing, nor are we able to follow-up on therapeutic efficacy when patients get treated. The GLIOMATCH project aims at improving the clinical outcome of GBM/pHGG patients by enabling immunology-based patient stratification to empower personalised matching of appropriate immunotherapy, while improving follow-up of clinical responses to existing/novel therapeutics. This will be achieved by integrating spatially resolved, multi-layered tissue maps (using integrated single-cell multiomics), with non-invasive MRI images. This integration will fuel into a novel MRI Radio-multiomics hub, that will be made available to clinical professionals through which they can perform tumour-host based patient stratification and personalised therapy matching while interpreting longitudinal follow-up and treatment efficacy. The proposed data-driven models will be developed by analysing the largest cohort of immuno-oncology (I/O) treated GBM/pHGG patients (n>300, including pre-post treatment samples) with matched controls (n>300) and exceptionally long-term surviving GBM patients (n~140), in which various tumour-host niches will be studied in how they respond to I/O perturbations and lead to improved clinical outcome. This will be empowered by deploying an UNCAN-compatible data lake, to which incremental data collection will be used to further refine the machine learning models, while proposing novel treatment options. This action is part of the Cancer Mission cluster of projects on Understanding (tumour-host interactions)""."

Conecta tu I+D

Entra hoy

¿Olvidó su contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores